Elevated Depressive Symptoms, Antidepressant Use, and Diabetes in a Large Multiethnic National Sample of Postmenopausal Women

Yunsheng Ma, MD, PhD
Raji Balasubramanian, ScD
Sherry L. Pagoto, PhD
Kristin L. Schneider, PhD
Annie L. Culver, BPharm
Barbara Olenzki, RD, MPH
Lesley Tinker, RD, PhD
Simin Liu, MD, ScD
Monika Safford, MD
Deidre M. Sepavich, MBA
Milagros C. Rosal, PhD
Judith K. Ockene, PhD, Med, MA
Mercedes Carnethon, PhD
Martha Zorn, MS
James R. Hebert, MSPH, ScD

OBJECTIVE—To examine elevated depressive symptoms and antidepressant use in relation to diabetes incidence in the Women’s Health Initiative.

RESEARCH DESIGN AND METHODS—A total of 161,808 postmenopausal women were followed for over an average of 7.6 years. Hazard ratios (HRs) estimating the effects of elevated depressive symptoms and antidepressant use on newly diagnosed incident diabetes were obtained using Cox proportional hazards models adjusted for known diabetes risk factors.

RESULTS—Multivariable-adjusted HRs indicated an increased risk of incident diabetes with elevated baseline depressive symptoms (HR 1.13 [95% CI 1.07–1.18]) and antidepressant use (HR 1.23 [95% CI 1.09–1.39]). These associations persisted through year 3 data, in which respective adjusted HRs were 1.23 (1.09–1.39) and 1.31 (1.14–1.50).

CONCLUSIONS—Postmenopausal women with elevated depressive symptoms who also use antidepressants have a greater risk of developing incident diabetes. In addition, longstanding elevated depressive symptoms and recent antidepressant medication use increase the risk of incident diabetes.

Elevated depressive symptoms and antidepressant use increase the risk of diabetest, and 2) the combination of elevated depressive symptoms and antidepressant use would have a compounded effect on incident diabetes risk.

RESEARCH DESIGN AND METHODS—The WHI enrolled 161,808 participants into clinical trials and an observational study (WHI-OS group) (7–10). Medication use, depressive symptoms, and diabetes status were collected repeatedly over an average of 7.6 years of follow-up. The study was approved by the institutional review boards of participating WHI institutions, and institutional review board exemption for the current investigation was obtained at the University of Massachusetts Medical School.

Diabetes status was determined by self-report of ever having received a physician diagnosis of and/or treatment for diabetes when not pregnant. Diabetes status was recorded at baseline and annually. This method is a reliable indicator of diagnosed diabetes, validated with medication and laboratory data assessments (11). Time to diabetes was calculated as the interval between the enrollment date and the earliest of the following: 1) the date of the annual medical history update when new diabetes status was ascertained (positive outcome); 2) the date of the last annual medical update during which diabetes status could be ascertained (censorship); or 3) the date of death (censorship).

Depressive symptoms at baseline and year 3 were measured using the Center for Epidemiological Studies Depression Scale (CES-D) six-item form (12). A cut point of five or higher categorized subjects as having elevated depressive symptoms (13). Medication names from container labels provided by participants were matched to the Master Drug Database (Medi-Span, Indianapolis, IN) at baseline and year 3. Based on the Master Drug Database classification, a binary indicator for antidepressant medication use was created.
Statistical analyses

Among 152,250 women who were reported to have diabetes at baseline and who had complete relevant data at baseline, Cox proportional hazards models were used to model the instantaneous hazard of diabetes as a function of elevated depressive symptoms and antidepressant medication use. Models were stratified on the WHI participant condition to allow for varying baseline hazard functions in relation to elevated depressive symptoms and antidepressant use within the WHI-OS and the different WHI clinical trial arms. The multivariate model adjusted for potential confounders including age, race/ethnicity, education, smoking status, BMI, recreational physical activity, alcohol intake, dietary energy intake, family history of diabetes, and hormone therapy use.

Longitudinal analysis was based on a subset of 70,874 women from the WHI-OS arm with data available on both depressive symptoms and antidepressant use. Elevated depressive symptoms at baseline and the year 3 visit were coded as follows: 0 = never any depressive symptoms (reference category); 1 = depressive symptoms at baseline only; 2 = depressive symptoms at year 3 only; and 3 = depressive symptoms at baseline and year 3. Antidepressant use was coded similarly.

Evidence of a multiplicative interaction effect at baseline and longitudinally was assessed in Cox proportional hazards models that included main effects and a multiple interaction term.

RESULTS—At baseline, 15.5% of women were above the depression cutoff on the CES-D and were defined as having elevated depressive symptoms, and 6.9% of women reported using antidepressants. The cumulative incidence of self-reported diabetes was 6.7%. Self-reported diabetes incidence rates were 8.6% for women with elevated depressive symptoms and 6.3% for those without (Table 1). In unadjusted models, elevated depressive symptoms were significantly related to diabetes risk (unadjusted HR 1.38 [95% CI 1.32–1.45]). The multivariate-adjusted HR was 1.13 (1.07–1.20). Antidepressant use also was significantly related to diabetes risk (unadjusted HR 1.23 [95% CI 1.09–1.39]), whereas HRs for those who reported antidepressant use only at year 3 (1.44 [1.26–1.66]) and who reported antidepressant use at both time points were significant (1.31 [1.14–1.50]). There was no evidence of a significant multiplicative interaction between longitudinal measures of elevated depressive symptoms and antidepressant use. Although the test of the proportional hazards assumption failed (P < 0.001), elevated depressive symptoms and antidepressant use were found to be significantly associated with diabetes risk in accelerated failure time models that allowed nonproportional hazards over time.

Table 1—HRs of diabetes associated with elevated depressive symptoms and antidepressant medication use at baseline and the year 3 visit in the WHI, estimated from Cox proportional hazards models

| Primary exposure variable | (n [self-reported incident diabetes %]) | Unadjusted HR (95% CI)* | HR (95% CI) adjusted for age and race† | HR (95% CI) from the multivariate model‡ |
|---------------------------|----------------------------------------|-------------------------|----------------------------------------|----------------------------------------|
| **Baseline analyses (n = 152,250)** | | | | |
| Elevated depressive symptoms | | | | |
| Yes | (23,541 [8.6]) | 1.38 (1.32–1.45) | 1.34 (1.27–1.41) | 1.13 (1.07–1.20) |
| No | (128,709 [6.3]) | 1.00 | 1.00 | 1.00 |
| Antidepressant medication use | | | | |
| Yes | (10,512 [8.2]) | 1.30 (1.22–1.40) | 1.42 (1.32–1.52) | 1.18 (1.10–1.28) |
| No | (141,738 [6.6]) | 1.00 | 1.00 | 1.00 |
| **Longitudinal analyses (n = 70,874)** | | | | |
| Elevated depressive symptoms | | | | |
| At baseline and year 3 | (4,554 [8.32]) | 1.74 (1.57–1.94) | 1.67 (1.50–1.86) | 1.23 (1.09–1.39) |
| At baseline only | (3,691 [5.96]) | 1.22 (1.09–1.36) | 1.21 (1.08–1.35) | 0.99 (0.87–1.12) |
| At year 3 only | (6,623 [6.37]) | 1.32 (1.19–1.46) | 1.31 (1.18–1.45) | 1.06 (0.95–1.18) |
| Never | (54,004 [4.92]) | 1.00 | 1.00 | 1.00 |
| Antidepressant medication use | | | | |
| At baseline and year 3 | (3,466 [7.24]) | 1.46 (1.28–1.66) | 1.60 (1.41–1.82) | 1.31 (1.14–1.50) |
| At baseline only | (1,530 [5.75]) | 1.14 (0.92–1.41) | 1.19 (0.96–1.47) | 0.92 (0.73–1.15) |
| At year 3 only | (3,223 [7.51]) | 1.50 (1.32–1.71) | 1.61 (1.42–1.84) | 1.44 (1.26–1.66) |
| Never | (62,655 [5.13]) | 1.00 | 1.00 | 1.00 |

*Cox proportional hazards model including elevated depressive symptoms or antidepressant use. †Cox proportional hazards model including elevated depressive symptoms or antidepressant use, while adjusting for age and race/ethnicity. ‡Cox proportional hazards model, including both elevated depressive symptoms and antidepressant use jointly, while adjusting for age, race/ethnicity, education, smoking status at baseline, BMI, hours of recreational activity per week, alcohol intake, total daily energy intake, family history of diabetes, and hormone therapy use.

care.diabetesjournals.org
CONCLUSIONS—Elevated depressive symptoms and antidepressant use at baseline were independently associated with an increased risk of diabetes among postmenopausal women, but there was no compounded effect of elevated depressive symptoms and antidepressant use. Our longitudinal analyses indicate that only longstanding elevated depressive symptoms increase the risk of incident diabetes, whereas antidepressant use at 3 years is associated with a dramatically elevated risk regardless of its presence at baseline. Recent antidepressant medication may increase risk of incident diabetes.

Because self-report of diabetes incidence may be imprecise, we conducted sensitivity analyses using a fasting glucose ≥126 mg/dL to identify diabetes. Although results were not significant likely because of small sample size, the trends observed were similar to analysis results using self-reported diabetes. Because elevated depressive symptoms were assessed at only two time points, some cases may have been missed (14). Likewise, women who began and then discontinued antidepressants in between collection points would be missed. However, antidepressants often are used long-term (for ~5–7.5 years) (15).

Acknowledgments—This research was supported by a grant to Y.M. from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1-R21-DK-083700-01A1). It was also supported in part by NIDDK Center Grant 5-P30-DK-32520. Y.M., S.L.P., and M.C.R. are members of the University of Massachusetts Diabetes and Endocrinology Research Center (DK-32520). The WHI Program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services (contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221). A list of WHI program investigators is available in the Supplementary Data.

No potential conflicts of interest relevant to this article were reported.

Y.M. wrote the manuscript and researched data. R.B. performed data analyses and reviewed and edited the manuscript. S.L.P., K.L.S., A.L.C., B.O., L.T., S.L., M.S., D.M.S., M.C.R., J.K.O., M.C., and J.R.H. contributed to discussion and reviewed and edited the manuscript. M.Z. performed data analyses and reviewed and edited the manuscript. The authors thank the principal investigators of all WHI clinical centers and the data coordinating center for their contribution to the study. They are indebted to the dedicated and committed participants of the WHI.

References
1. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouve F. Depression as a risk factor for the onset of type 2 diabetes mellitus: a meta-analysis. Diabetologia 2006; 49:837–845
2. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008;31:2383–2390
3. Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79:61–67
4. Rubin RR, Ma Y, Marrero DG, et al.; Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the Diabetes Prevention Program. Diabetes Care 2008; 31:420–426
5. Andersohn F, Schade R, Suisa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009;166:991–998
6. Campayo A, de Jonge P, Roy JF, et al.; ZARADEMP Project. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry 2010;167:580–588
7. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61–109
8. Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women’s Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(Suppl.):S87–S97
9. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(Suppl.): S78–S86
10. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13(Suppl.):S107–S121
11. Margolis KL, Lihong Qi, Brzyski R, et al.; Women Health Initiative Investigators. Validity of diabetes self-reports in the Women’s Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240–247
12. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 1994;10:77–84
13. Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women: the Women’s Health Initiative (WHI). Arch Intern Med 2004;164:289–298
14. Andrews G. Reducing the burden of depression. Can J Psychiatry 2008;53:420–427
15. Petty DR, House A, Knapp P, Raynor T, Zernamsky A. Prevalence, duration and indications for prescribing of anidepressants in primary care. Age Ageing 2006;35:523–526